Exact Sciences Stock Forecast, Price & News

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Exact Sciences stock.
View analyst ratings for Exact Sciences or view top-rated stocks.

Wall Street analysts have given Exact Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Exact Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Exact Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Exact Sciences.

Exact Sciences will be holding an earnings conference call on Tuesday, May 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Exact Sciences Co. (NASDAQ:EXAS) issued its quarterly earnings data on Monday, February, 15th. The medical research company reported ($2.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $2.60. The medical research company had revenue of $466.34 million for the quarter, compared to analyst estimates of $465.98 million. Exact Sciences had a negative trailing twelve-month return on equity of 11.71% and a negative net margin of 25.27%.
View Exact Sciences' earnings history.

Exact Sciences' stock was trading at $57.82 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EXAS stock has increased by 124.9% and is now trading at $130.04.
View which stocks have been most impacted by COVID-19.

14 equities research analysts have issued 12 month price objectives for Exact Sciences' stock. Their forecasts range from $92.00 to $226.00. On average, they expect Exact Sciences' share price to reach $150.33 in the next year. This suggests a possible upside of 15.6% from the stock's current price.
View analysts' price targets for Exact Sciences or view top-rated stocks among Wall Street analysts.

141 employees have rated Exact Sciences CEO Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among Exact Sciences' employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Exact Sciences include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Incyte (INCY), Novavax (NVAX), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of EXAS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), PayPal (PYPL), Square (SQ), Advanced Micro Devices (AMD), The Walt Disney (DIS) and AbbVie (ABBV).

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Exact Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.09%), Thompson Investment Management Inc. (0.07%), Moody National Bank Trust Division (0.06%), Royal London Asset Management Ltd. (0.03%), DnB Asset Management AS (0.02%) and EFG Asset Management Americas Corp. (0.02%). Company insiders that own Exact Sciences stock include G Bradley Cole, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Sarah Condella, Scott C Johnson and Torsten Hoof.
View institutional ownership trends for Exact Sciences.

EXAS stock was sold by a variety of institutional investors in the last quarter, including Thompson Investment Management Inc., EFG Asset Management Americas Corp., Golden Green Inc., AdvisorNet Financial Inc, Pacer Advisors Inc., Moody National Bank Trust Division, and Valeo Financial Advisors LLC. Company insiders that have sold Exact Sciences company stock in the last year include Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Sarah Condella, and Torsten Hoof.
View insider buying and selling activity for Exact Sciences or view top insider-selling stocks.

EXAS stock was bought by a variety of institutional investors in the last quarter, including Scout Investments Inc., DnB Asset Management AS, Polianta Ltd, Chicago Capital LLC, ERn Financial LLC, Phoenix Wealth Advisors, Royal London Asset Management Ltd., and FDx Advisors Inc..
View insider buying and selling activity for Exact Sciences or or view top insider-buying stocks.

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EXAS stock can currently be purchased for approximately $130.04.

Exact Sciences has a market capitalization of $21.99 billion and generates $876.29 million in revenue each year. The medical research company earns $-83,990,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

Exact Sciences employs 4,800 workers across the globe.

Exact Sciences was founded in 1995.

The official website for Exact Sciences is www.exactsciences.com.

Exact Sciences is headquartered at 5505 ENDEAVOR LANE, MADISON WI, 53719.

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The medical research company can be reached via phone at 608-535-8815 or via email at [email protected]